Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JDTic is a powerful antagonist of kappa-opioid receptors (KOR), effectively inhibiting the antinociceptive effects induced by the κ-agonist U50, 488.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 106.00 | |
25 mg | 10-14 weeks | $ 668.00 | |
50 mg | 10-14 weeks | $ 868.00 | |
100 mg | 10-14 weeks | $ 1,290.00 |
Description | JDTic is a powerful antagonist of kappa-opioid receptors (KOR), effectively inhibiting the antinociceptive effects induced by the κ-agonist U50, 488. |
In vivo | JDTic administered intraperitoneally (i.p.) at a dose of 10 mg/kg effectively reduces alcohol self-administration, inhibits cue-induced alcohol seeking, and selectively antagonizes the effects of a kappa-opioid receptor (KOR) agonist 2 hours after treatment. At a higher dose (30 mg/kg) given intragastrically (i.g.), JDTic significantly prevents U50,488-induced diuresis in rats. When administered subcutaneously (s.c.) in doses ranging from 2.5 to 16 mg/kg, JDTic dose-dependently inhibits the antinociceptive effects of nicotine in the tail-flick test without affecting outcomes in the hot-plate test or altering body temperature in nicotine-injected mice. Additionally, a 3 mg/kg i.p. dose of JDTic effectively ameliorates anxiety-like behavior in a rat model of hangover anxiety. |
Molecular Weight | 538.55 |
Formula | C28H41Cl2N3O3 |
CAS No. | 785835-79-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (185.68 mM), Sonication is recommended.
H2O: 50 mg/mL (92.84 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JDTic dihydrochloride 785835-79-2 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK JDTic JDTic Dihydrochloride inhibitor inhibit